Fuji Pharma Co

Fuji Pharma Co EBIT

The EBIT of Fuji Pharma Co (4554.T) as of Oct 28, 2026 is 4.99 B JPY. In the previous year, EBIT was 3.88 B JPY — a change of 28.58% (higher).

EBIT

4.99 BJPY

YoY

28.58%

Last updated:

In 2025, Fuji Pharma Co's EBIT was 4.99 B JPY, a 28.58% increase from the 3.88 B JPY EBIT recorded in the previous year.

The Fuji Pharma Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
3.86 B JPY
Jan 1, 2024
3.88 B JPY
Jan 1, 2025
4.99 B JPY
Jan 1, 2026 (e)
3.36 B JPY
Jan 1, 2027 (e)
8.13 B JPY
Jan 1, 2028 (e)
9.01 B JPY
Jan 1, 2029 (e)
8.36 B JPY
Jan 1, 2030 (e)
9.31 B JPY
The Fuji Pharma Co EBIT history
YEAREBITYoY
est9.31 BJPY+11.33%
est8.36 BJPY-7.14%
est9.01 BJPY+10.82%
est8.13 BJPY+142.26%
est3.36 BJPY-32.76%
4.99 BJPY+28.58%
3.88 BJPY+0.57%
3.86 BJPY+2.14%
3.78 BJPY+11.05%
3.40 BJPY+8.34%
3.14 BJPY-24.77%
4.17 BJPY-5.76%
4.43 BJPY+1.84%
4.35 BJPY+21.85%
3.57 BJPY+9.78%
3.25 BJPY+2.46%
3.17 BJPY-2.70%
3.26 BJPY+18.73%
2.75 BJPY-22.97%
3.57 BJPY+10.30%
3.23 BJPY+31.30%
2.46 BJPY+19.18%
2.07 BJPY-1.76%
2.10 BJPY+37.27%
1.53 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fuji Pharma Co Revenue

Fuji Pharma Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
40.89 B JPY
3.86 B JPY
3.44 B JPY
Jan 1, 2024
46.14 B JPY
3.88 B JPY
6.15 B JPY
Jan 1, 2025
51.68 B JPY
4.99 B JPY
3.00 B JPY
Jan 1, 2026 (e)
63.00 B JPY
3.36 B JPY
2.34 B JPY
Jan 1, 2027 (e)
72.00 B JPY
8.13 B JPY
5.89 B JPY
Jan 1, 2028 (e)
77.00 B JPY
9.01 B JPY
6.54 B JPY
Jan 1, 2029 (e)
77.05 B JPY
8.36 B JPY
6.06 B JPY
Jan 1, 2030 (e)
79.96 B JPY
9.31 B JPY
6.77 B JPY

Fuji Pharma Co Margins

Fuji Pharma Co stock margins

The Fuji Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fuji Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fuji Pharma Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
37.60 %
9.44 %
8.40 %
Jan 1, 2024
35.79 %
8.41 %
13.32 %
Jan 1, 2025
37.33 %
9.66 %
5.81 %
Jan 1, 2026 (e)
37.33 %
5.33 %
3.71 %
Jan 1, 2027 (e)
37.33 %
11.29 %
8.18 %
Jan 1, 2028 (e)
37.33 %
11.70 %
8.49 %
Jan 1, 2029 (e)
37.33 %
10.86 %
7.87 %
Jan 1, 2030 (e)
37.33 %
11.65 %
8.46 %

Fuji Pharma Co Stock analysis

What does Fuji Pharma Co do? Fuji Pharma Co Ltd is a Japanese company specializing in the healthcare industry. The company was founded in 2001 and is headquartered in Tokyo, Japan. It is listed on the Tokyo Stock Exchange and employs over 1,000 employees. Fuji Pharma's business model is to provide its customers with innovative and high-quality products that contribute to improving health and well-being. The company specializes in several business areas, including the development, manufacturing, and marketing of pharmaceutical products, production of OEM products for other companies, and manufacturing of dietary supplements and cosmetics. An important area for Fuji Pharma is the development and production of pharmaceuticals. The company ensures that its medications meet the highest requirements and international standards. This includes research and development of new products. The company has its own research department specializing in the development of medications that can be used in serious diseases such as cancer, diabetes, and cardiovascular diseases. In addition, Fuji Pharma is also involved in the production of OEM products for other companies. The company ensures the manufacture of medications and medical products for other pharmaceutical companies, meeting the highest quality standards and customer requirements. Fuji Pharma is proud to be a trusted partner for its customers and provides its services according to the requirements of its customers. In addition to these two divisions, Fuji Pharma also produces dietary supplements and cosmetics for the domestic and international markets. These products are designed for consumers who want to improve their health and well-being. The company places great emphasis on the development of natural and safe ingredients for its products and ensures the highest standards of quality and safety. Fuji Pharma has also specialized in the Japanese market for medical devices, particularly in the field of home respiratory devices. The company has developed a new generation of respiratory therapy devices that are safe and easy to use, providing better well-being and quality of life for patients with respiratory diseases. In addition to its business areas, Fuji Pharma also has various products in its portfolio that are known for their quality and effectiveness. One such product is "Efil," a medication used in the treatment of erectile dysfunction disorders. The medication is available in Japan and other Asian countries and has already been used by over 200,000 patients. Fuji Pharma continuously strives to improve its research and development activities and develop new innovative products and services for the healthcare industry. The company aims to bring its products and services to the international market and satisfy its customers in Japan and worldwide. Fuji Pharma Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Fuji Pharma Co's EBIT

Fuji Pharma Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Fuji Pharma Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Fuji Pharma Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Fuji Pharma Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Fuji Pharma Co stock

EBIT of Fuji Pharma Co is 4.99 B JPY in 2025.

EBIT of Fuji Pharma Co changed from 3.88 B JPY to 4.99 B JPY, representing a 28.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Fuji Pharma Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Fuji Pharma Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Fuji Pharma Co

All Key Metrics — Fuji Pharma Co